BiotechTube
NeuroQore

NeuroQore

Cambridge, United States· Est.
neuroqore.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NeuroQore is an early-stage biotech startup founded in 2021, targeting a critical unmet need in mental health: rapid and effective treatment for patients with treatment-resistant depression (TRD) and acute suicidality. The company is developing novel neuromodulation therapies intended to overcome the limitations of current standards like electroconvulsive therapy (ECT), which has a delayed onset and significant side effects. Operating from the biotech hub of Cambridge, MA, NeuroQore is positioned to innovate in a high-burden therapeutic area with substantial market potential, though it remains in a pre-clinical, pre-revenue stage of development.

PsychiatryNeuroscience

Technology Platform

Pioneering neuromodulation treatments (specific modality undisclosed) targeting neural circuits for neurobehavioral conditions, with an aim to be faster-acting and better tolerated than current standards like electroconvulsive therapy (ECT).

Opportunities

The significant unmet need in TRD and acute suicidality, coupled with the drawbacks of ECT, creates a large addressable market for a superior therapy.
Advances in neuroscience and neuroengineering provide a growing toolkit for developing more precise and effective neuromodulation technologies.

Risk Factors

High scientific risk that the undisclosed technology may not prove effective or safe.
Intense competition from both pharmacological (e.g., psychedelics, ketamine) and device-based (rTMS, DBS) therapies in development for TRD.
Dependence on securing substantial venture funding to advance through costly clinical trials.

Competitive Landscape

NeuroQore competes in the treatment-resistant depression space against approved therapies like Spravato (esketamine), rTMS devices, and ECT itself. It also faces competition from a pipeline of novel drugs (psychedelics, glutamatergic agents) and advanced neuromodulation approaches from companies like Magnus Medical, BrainsWay, and Abbott (DBS). Success requires demonstrating clear differentiation in speed of onset and tolerability.

More companies in Neuroscience & CNS →More companies in United States →